OSTX vs PALI

OS Therapies Incorporated vs Palisade Bio, Inc. — Valuation Comparison 2026

OSTX

Biotechnology
OS Therapies Incorporated
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.98
Last close
Models
6/13
Active
VS

PALI

Biotechnology
Palisade Bio, Inc.
Quality
4.0
out of 10
Value Trap
27
LOW
Price
$2.06
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType OSTX Fair ValueOSTX Upside PALI Fair ValuePALI Upside
Bayesian DCF Intrinsic $0.52 -74.0% $0.97 -52.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.04 -98.1% $0.86 -58.1%
PWERM Option-Based $2.10 +5.9% $1.99 -3.2%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OSTX vs PALI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OSTX vs PALI — Which Stock Is More Undervalued?

PALI scores higher with a 4.0/10 quality rating vs OSTX's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing OS Therapies Incorporated (OSTX) and Palisade Bio, Inc. (PALI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OSTX currently trades at $1.98 with a QOC of 3.1/10, while PALI trades at $2.06 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).